Improving therapeutic potential in breast cancer via histone deacetylase inhibitor loaded nanofibrils

Area of Science:

• Biochemistry
• Nanotechnology
• Oncology

Background:

• Epigenetic modifications are crucial in cancer progression and represent therapeutic targets.
• Histone deacetylase inhibitors, like SAHA, show potential in inhibiting cancer cell growth, including breast cancer (BC).

Purpose of the Study:

• To evaluate suberoyl anilide hydroxamic acid (SAHA)-loaded beta-lactoglobulin (β-lg) nanofibrils as a drug delivery system for triple-negative BC.
• To assess the impact of this system on cancer cell cycle, apoptosis, reactive oxygen species, and mitochondrial membrane potential.

Main Methods:

• Utilized SAHA-loaded β-lg nanofibrils for drug delivery in triple-negative BC cell lines.
• Assessed cell cycle progression, apoptosis rates, reactive oxygen species levels, and mitochondrial membrane potential.

Main Results:

• The combination of SAHA and β-lg nanofibrils showed enhanced inhibition of cell growth and induced cell cycle arrest.
• Apoptosis rates were higher with the combined therapy (43.78%) compared to SAHA alone (40.09%).
• The system effectively targeted cancer cells at low concentrations without promoting drug resistance.

Conclusions:

• SAHA-loaded β-lg nanofibrils represent a promising drug delivery strategy for triple-negative breast cancer.
• This nanocarrier system enhances the therapeutic efficacy of SAHA, offering a potential new avenue for BC treatment.